Answer 6 questions and see what patients with similar goals are running: which peptides they use, typical dosing, injection schedule, reconstitution steps, cycle length, and when they pause
Diabetes Care 41 , 23612369 (2018)
Researchers coming from GLP-1 work will recognize this part of the mechanism
Only authorised medicinal products are subject to regulatory control by competent authorities with regard to composition, quality, safety and efficacy
This review may provide a background to guide future research about the cellular mechanisms of GLP-1-induced feeding inhibition
Geetika Arora, an endocrinologist at Northwell's Phelps Hospital, puts it simply: "The trade-off comes down to convenience versus maximum weight loss." In a Lilly-funded trial published by The Lancet, patients on 12 to 36 milligrams of orforglipron lost an average of 15 to 20 pounds, compared with 8 to 11 pounds for those on 7 to 14 milligrams of Rybelsus